New immune drug FL115 takes on Hard-to-Treat cancers
NCT ID NCT07131189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests FL115, a protein designed to boost the body's immune cells to fight cancer. It involves 30 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FL115 (a lab-made protein that boosts immune cells to fight cancer)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so the drug may not be effective or could cause unexpected side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED / METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China